M
Michelle A. Detry
Publications - 18
Citations - 1736
Michelle A. Detry is an academic researcher. The author has contributed to research in topics: Randomized controlled trial & Medicine. The author has an hindex of 8, co-authored 18 publications receiving 791 citations.
Papers
More filters
Journal ArticleDOI
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.
Derek C. Angus,Lennie P. G. Derde,Farah Al-Beidh,Djillali Annane,Yaseen M. Arabi,Abi Beane,Wilma van Bentum-Puijk,Lindsay R. Berry,Zahra Bhimani,Marc J. M. Bonten,Charlotte Bradbury,Frank M. Brunkhorst,Meredith Buxton,Adrian Buzgau,Allen C. Cheng,Menno de Jong,Michelle A. Detry,Lise J Estcourt,Lise J Estcourt,Mark Fitzgerald,Herman Goossens,Cameron Green,Rashan Haniffa,Alisa Higgins,Christopher M. Horvat,Sebastiaan J. Hullegie,Peter Kruger,Francois Lamontagne,Patrick R. Lawler,Kelsey Linstrum,Edward Litton,Elizabeth Lorenzi,John E. A. Marshall,John E. A. Marshall,Daniel F. McAuley,Anna McGlothin,Shay McGuinness,Shay McGuinness,Shay McGuinness,Bryan J. McVerry,Stephanie K. Montgomery,Paul R Mouncey,Srinivas Murthy,Alistair Nichol,Rachael Parke,Rachael Parke,Rachael Parke,Jane Parker,Kathryn M Rowan,Ashish Sanil,Marlene Santos,Christina Saunders,Christopher W. Seymour,Anne Turner,Frank L. van de Veerdonk,Balasubramanian Venkatesh,Balasubramanian Venkatesh,Ryan Zarychanski,Scott M. Berry,Roger J. Lewis,Roger J. Lewis,Colin McArthur,Steven A R Webb,Steven A R Webb,Steven A R Webb,Anthony C. Gordon +65 more
TL;DR: To determine whether hydrocortisone improves outcome for patients with severe COVID-19, an ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin was conducted.
Journal ArticleDOI
Analyzing Repeated Measurements Using Mixed Models
Michelle A. Detry,Yan Ma +1 more
TL;DR: This Guide to Statistics and Methods discusses analyzing repeated measurements using mixed models and the importance of knowing which models to use for each measurement.
Journal ArticleDOI
The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design.
Derek C. Angus,Scott M. Berry,Roger J. Lewis,Farah Al-Beidh,Yaseen M. Arabi,Wilma van Bentum-Puijk,Zahra Bhimani,Marc J.M. Bonten,Kristine Broglio,Frank M. Brunkhorst,Allen C. Cheng,Jean Daniel Chiche,Menno de Jong,Michelle A. Detry,Herman Goossens,Anthony C. Gordon,Cameron Green,Alisa Higgins,Sebastiaan J. Hullegie,Peter Kruger,Francois Lamontagne,Edward Litton,John Marshall,John Marshall,Anna McGlothlin,Shay McGuinness,Shay McGuinness,Paul R Mouncey,Srinivas Murthy,Alistair Nichol,Alistair Nichol,Genevieve K. O'Neill,Rachael Parke,Rachael Parke,Jane Parker,Gernot Rohde,Kathryn M Rowan,Anne Turner,Paul J Young,Paul J Young,Lennie P. G. Derde,Lennie P. G. Derde,Colin McArthur,Colin McArthur,Steven A R Webb,Steven A R Webb,Steven A R Webb +46 more
TL;DR: A large, international trial that combines features of adaptive platform trials with pragmatic point-of-care trials to determine best treatment strategies for patients admitted to an intensive care unit with severe community-acquired pneumonia is presented.
Journal ArticleDOI
Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.
Christopher C Butler,Jienchi Dorward,Ly-Mee Yu,Oghenekome Gbinigie,Gail Hayward,Benjamin R. Saville,Oliver van Hecke,Nick Berry,Michelle A. Detry,Christina Saunders,Mark Fitzgerald,Victoria Harris,Mahendra Patel,Simon de Lusignan,Emma Ogburn,Philip Evans,Nicholas P B Thomas,FD Richard Hobbs +17 more
TL;DR: In this paper, the effectiveness of azithromycin to treat suspected COVID-19 among people in the community who had an increased risk of complications was evaluated in a randomized trial.
Journal ArticleDOI
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.
Ly-Mee Yu,Mona Bafadhel,Jienchi Dorward,Jienchi Dorward,Gail Hayward,Benjamin R. Saville,Oghenekome Gbinigie,Oliver van Hecke,Emma Ogburn,Philip Evans,Philip Evans,Nicholas P B Thomas,Nicholas P B Thomas,Mahendra G Patel,Duncan Richards,Nicholas Berry,Michelle A. Detry,Christina Saunders,Mark Fitzgerald,Victoria Harris,Milensu Shanyinde,Simon de Lusignan,Monique Andersson,Peter J. Barnes,Richard Russell,Dan V. Nicolau,Dan V. Nicolau,Sanjay Ramakrishnan,FD Richard Hobbs,Christopher C Butler,Nicholas Pb Thomas,Christina T Saunders,Richard Ek Russell +32 more
TL;DR: A previous efficacy trial found benefit from inhaled budesonide for COVID-19 in patients not admitted to hospital, but effectiveness in high-risk individuals is unknown as mentioned in this paper.